Template:Available forms of estradiol

From blackwiki
Jump to navigation Jump to search

Available forms of estradiol[lower-alpha 1]

Route Ingredient Form Dose[lower-alpha 2] Brand names[lower-alpha 3]
Oral Template:No selflink Tablet 0.1, 0.2, 0.5, 1, 2, 4 mg Estrace, Ovocyclin
Template:No selflink Tablet 0.5, 1, 2, 4 mg Progynova
Transdermal Template:No selflink Patch 14, 25, 37.5, 50, 60, 75, 100 µg/d Climara, Vivelle
Gel pump 0.06% (0.52, 0.75 mg/pump) Elestrin, EstroGel
Gel packet 0.1% (0.25, 0.5, 1.0 mg/pk.) DiviGel, Sandrena
Emulsion 0.25% (25 µg/pouch) Estrasorb
Spray 1.53 mg/spray Evamist
Vaginal Template:No selflink Tablet 10, 25 µg Vagifem
Cream 0.01% (0.1 mg/gram) Estrace
Insert 4, 10 µg Imvexxy
Ring 2 mg/ring (7.5 µg/d, 3 mon.) Estring
Template:No selflink Ring 50, 100 µg/d, 3 months Femring
Injection[lower-alpha 4] Template:No selflink Microspheres 1 mg/mL Juvenum E
Template:No selflink Oil solution 0.167, 0.2, 0.333, 1, 1.67, 2, 5, 10, 20, 25 mg/mL Progynon-B
Template:No selflink Oil solution 1, 3, 5 mg/mL Depo-Estradiol
Template:No selflink Oil solution 5, 10, 20, 40 mg/mL Progynon Depot
Implant Template:No selflink Pellet 20, 25, 50, 100 mg, 6 mon. Estradiol Implants
Template documentation[view] [edit] [history] [purge]

Use {{Available forms of estradiol|floatleft=yes}} to floatleft, and {{Available forms of estradiol|floatright=yes}} to floatright - by default table is centered as on this page.

See also

References

  1. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
  2. Rogerio A. Lobo (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 177, 217–226, 770–771. ISBN 978-0-08-055309-2.
  3. Tommaso Falcone; William W. Hurd (14 June 2017). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer. pp. 179–. ISBN 978-3-319-52210-4.
  4. Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 889, 1059–1060, 2153. ISBN 978-0-7817-1750-2.
  5. A. Kleemann; J. Engel; B. Kutscher; D. Reichert (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1167–1174. ISBN 978-3-13-179525-0.
  6. Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 276, 454–455, 566–567. ISBN 978-3-7692-2114-5.
  7. Krishna; Usha R. And Shah (1996). Menopause. Orient Blackswan. pp. 70–. ISBN 978-81-250-0910-8.
  8. "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN 0095-9561.
  9. http://www.medicines.org.au/files/secaerod.pdf
  10. https://www.drugs.com/international/estradiol.html
  11. Sahin FK, Koken G, Cosar E, Arioz DT, Degirmenci B, Albayrak R, Acar M (2008). "Effect of Aerodiol administration on ocular arteries in postmenopausal women". Gynecol. Endocrinol. 24 (4): 173–7. doi:10.1080/09513590701807431. PMID 18382901. 300 μg 17β-estradiol (Aerodiol®; Servier, Chambrayles-Tours, France) was administered via the nasal route by a gynecologist. This product is unavailable after March 31, 2007 because its manufacturing and marketing are being discontinued.
  12. Leo Jr. Plouffe; Veronica A. Ravnikar; Leon Speroff; Nelson B. Watts (6 December 2012). Comprehensive Management of Menopause. Springer Science & Business Media. pp. 271–. ISBN 978-1-4612-4330-4.
  13. University of California (1868-1952) (1952). Hospital Formulary and Compendium of Useful Information. University of California Press. pp. 49–. GGKEY:2UAAZRZ5LN0.
  14. Freimut A. Leidenberger (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 527–. ISBN 978-3-662-08110-5.


Cite error: <ref> tags exist for a group named "lower-alpha", but no corresponding <references group="lower-alpha"/> tag was found, or a closing </ref> is missing